CD274 and renal cell carcinoma: In an interim analysis, 22% achieved durable disease control, with notable responses demonstrated in the presence of BAP1 alterations, including one patient with a PR.96 In a phase 1 study (NCT03682289), the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, ceralasertib, is being examined as a single agent and in combination with olaparib or a PD-L1 inhibitor, durvalumab, across various solid tumor types, including advanced RCC.